Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2025 Earnings Call Transcript August 12, 2025Taysha Gene Therapies, Inc. misses on earnings expectations.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 23,555,648 | $54,413,547 | +117% | 0.92% |
| 2. | VenBio Select Advisor Kurt Von Emster | 21,700,000 | $50,127,000 | +9% | 0.88% |
| 3. | Octagon Capital Advisors Ting Jia | 12,592,500 | $29,088,675 | +18% | 6.38% |
| 4. | Siren L.L.C. Raymond Debbane | 11,014,737 | $25,444,042 | +70% | 1.32% |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 10,313,733 | $23,824,723 | +4106% | 0.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 750,000 | $2,062,500.00 | 2,841,704 | 2025-05-30 | Filing | |
| $2.25 | 1,333,333 | $2,999,999.25 | 1,333,333 | 2024-06-27 | Filing | |
| $1.63 | 100,000 | $163,000.00 | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | $14,820,000.30 | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | $350,000.10 | 999,381 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.33 | 33,000 | $76,890.00 | 258,042 | 2023-08-24 | Filing | |
| $0.70 | 5,344 | $3,740.80 | 8,871,747 | 2023-07-13 | Filing | |
| $0.71 | 80,528 | $57,029.93 | 8,877,091 | 2023-07-12 | Filing | |
| $0.70 | 18,100 | $12,735.16 | 8,957,619 | 2023-06-23 | Filing | |
| $0.70 | 10,508 | $7,383.97 | 8,975,719 | 2023-06-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 25,021,584 | $57,799,859 | 0.82% | |
| 2. | 16,865,082 | $38,958,339 | 0% | |
| 3. | 15,627,822 | $36,100,268 | 0% | |
| 4. | 13,303,775 | $30,731,719 | 0% | |
| 5. | 12,587,700 | $29,077,587 | 0% |
News See All
Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA)
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best strong buy penny stocks to buy now.
10 Best Strong Buy Penny Stocks to Buy Now
On July 28, Alan Rechtschaffen, UBS Global Wealth senior portfolio manager, appeared on CNBC’s ‘Money Movers’ to talk about the markets, his Fed outlook, and more.
BofA Securities Affirms ‘Buy’ Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the penny stocks that will skyrocket. On July 11, BofA Securities initiated coverage of the stock with a “Buy” rating and an $8 price target.
Needham Maintains a Buy on Taysha Gene Therapies (TSHA), Keeps PT at $8
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best biotech penny stocks to buy right now. On July 1, analyst Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies, Inc.
14 Best Biotech Penny Stocks to Buy Right Now
He acknowledged that biotech has been a “super tough sector” either way, as there are hundreds of publicly traded stocks that do not add up to anything in aggregate.
10 Penny Stocks That Will Skyrocket
Valuations in the equity markets sit at historical highs, raising questions about future market performance.
Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 best healthcare penny stocks to buy according to analysts.
10 Best Healthcare Penny Stocks to Buy According to Analysts
According to the Centers for Medicare & Medicaid Services (CMS), the US healthcare sector accounted for approximately 17.6% of GDP in 2023.
Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts.
Billionaire Hedge Funds
